To our knowledge, our research is the first to demonstrate that PA induces β-cell dysfunction via inhibiting the NAD+/AMPK/SIRT1/HIF-1α pathway, whereas NMN treatment can reverse PA-induced β-cell dysfunction by activating this pathway, providing an emerging perspective for the therapy of T2DM. This evidence concerns the gene PRKAA1 and type 2 diabetes mellitus.